Expert opinion on investigational drugs最新文献

筛选
英文 中文
Promising selective progesterone receptor modulators: what's new in female contraception? 前景看好的选择性孕酮受体调节剂:女性避孕的新动向?
IF 4.9 2区 医学
Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-11-18 DOI: 10.1080/13543784.2024.2422838
Anita Nelson, Marit Pearlman Shapiro
{"title":"Promising selective progesterone receptor modulators: what's new in female contraception?","authors":"Anita Nelson, Marit Pearlman Shapiro","doi":"10.1080/13543784.2024.2422838","DOIUrl":"10.1080/13543784.2024.2422838","url":null,"abstract":"<p><strong>Introduction: </strong>Selective progesterone receptor modulators (SPRMs), such as mifepristone and ulipristal acetate (UPA), have demonstrated high efficacy and safety as single-dose treatments for medication abortion and emergency contraception (EC). Other obstetrical and gynecologic applications have emerged, both for episodic and ongoing uses. The potential of these compounds to provide estrogen-free, ongoing contraception is promising; however, the rare, but serious, hepatic injury cases seen with UPA have put at least a temporary halt to further research in this area.</p><p><strong>Areas covered: </strong>This paper reviews the biophysical impacts and clinical applications of SPRMs in women's reproductive health, with a focus on the roles of mifepristone and UPA in family planning. Given the political environment, especially in the United States where these applications may be threatened, extensive description is dedicated to mechanisms of action of these agents.</p><p><strong>Expert opinion: </strong>Both mifepristone and ulipristal acetate are first-line options for single-use applications. There continues to be a need for estrogen-free ongoing contraception that does not have unpopular impacts on bleeding caused by contraceptive methods and for treatments for heavy menstrual bleeding. However, current restrictions on UPA limit longer term use. Perhaps other SPRMs without hepatic impacts may emerge to fill this need.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1187-1198"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what's new? 刺激胰岛素分泌的药物在治疗1型糖尿病的早期临床开发:有什么新进展?
IF 4.9 2区 医学
Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-12-12 DOI: 10.1080/13543784.2024.2439501
Xinyuan Ning, Kashif M Munir, Stephen N Davis
{"title":"Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what's new?","authors":"Xinyuan Ning, Kashif M Munir, Stephen N Davis","doi":"10.1080/13543784.2024.2439501","DOIUrl":"10.1080/13543784.2024.2439501","url":null,"abstract":"<p><strong>Introduction: </strong>Type 1 diabetes is a chronic autoimmune condition characterized by the selective destruction of insulin-producing beta cells in the pancreas. The etiology of T1D is multifactorial, with a combination of genetic susceptibility and environmental triggers believed to underlie beta-cell destruction. Preserving and prolonging beta-cell function in T1D is a pivotal therapeutic objective that can mitigate disease progression and improve glycemic control.</p><p><strong>Areas covered: </strong>Insulin secretagogues have long been used in the management of type 2 diabetes, but do not have a significant beneficial effect in individuals with long-standing type 1 diabetes. Enhancement of beta-cell function early in the course of type 1 diabetes may offer important benefits in glycemic control and reduced hypoglycemia risk. Glucagon-like peptide-1 receptor agonists, glucokinase activators, free fatty acid receptor agonists, and glimins are drug classes which may offer benefit in enhancing insulin secretion in individuals with type 1 diabetes.</p><p><strong>Expert opinion: </strong>Drugs which enhance insulin secretion in individuals may offer clinical benefits to individuals with type 1 diabetes. However, the lack of beta-cell capacity introduces a challenge without regeneration of insulin-producing cells. Stem cell therapies combined with regulation of islet autoimmunity may offer the best prospect of increased insulin secretion in individuals with T1D.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1199-1208"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fibroblast growth factor therapies in biliary tract cancers: current and future state. 成纤维细胞生长因子治疗胆道肿瘤:目前和未来的状态。
IF 4.9 2区 医学
Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-12-04 DOI: 10.1080/13543784.2024.2430201
Teerada Siripoon, Conor O'Donnell, Zhaohui Jin, Amit Mahipal
{"title":"Fibroblast growth factor therapies in biliary tract cancers: current and future state.","authors":"Teerada Siripoon, Conor O'Donnell, Zhaohui Jin, Amit Mahipal","doi":"10.1080/13543784.2024.2430201","DOIUrl":"10.1080/13543784.2024.2430201","url":null,"abstract":"<p><strong>Introduction: </strong>Cholangiocarcinoma is the rare and aggressive tumor with poor prognosis and limited therapeutic options. Recently, there have been promising developments in molecular targeted therapies for patients following the progression of first-line chemotherapy and immunotherapy combinations. Dysregulation of fibroblast Growth Factor Receptor (FGFR) signaling is significantly associated with tumorigenesis of intrahepatic cholangiocarcinoma and has been identified as a targetable alteration. This was possible through the discovery of crucial insights into the biochemical mechanisms and pathophysiology of the FGFR pathway.</p><p><strong>Areas covered: </strong>This review summarizes the current state of FGFR targeted therapies, mechanisms of resistance, and future directions for FGFR-targeted therapies in patients with cholangiocarcinoma.</p><p><strong>Expert opinion: </strong>Currently, pemigatinib and futibatinib are FDA approved FGFR-targeted therapies that have demonstrated remarkable responses. However, there is still a significant proportion of patients whose disease remains intrinsically resistant to treatment and most patients eventually develop secondary resistance after an initial response. Additionally, unique side effects of FGFR inhibitors may limit their efficacy in clinical practice and can have detrimental effects on quality of life. Several novel FGFR inhibitors are currently being investigated to overcome resistance mechanisms and reduce toxicities.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1245-1255"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke. QHRD106作为一种安全有效的长效降凝血酶药物,可能有助于缺血性中风,这是首次进行人体研究。
IF 4.9 2区 医学
Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-11-19 DOI: 10.1080/13543784.2024.2430200
Lei Huang, Runbin Sun, Hengwen Song, Zhiyou Chen, Yuxin Hong, Haoyi Yang, Yuwen Zhang, Lijun Wei, Fei Fei, Juan Li
{"title":"The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke.","authors":"Lei Huang, Runbin Sun, Hengwen Song, Zhiyou Chen, Yuxin Hong, Haoyi Yang, Yuwen Zhang, Lijun Wei, Fei Fei, Juan Li","doi":"10.1080/13543784.2024.2430200","DOIUrl":"10.1080/13543784.2024.2430200","url":null,"abstract":"<p><strong>Background: </strong>This study assessed the pharmacokinetics (PK), pharmacodynamics (PD) and safety of QHRD106, and made a comparison with urinary kallindinogenase (UKN) in healthy volunteers.</p><p><strong>Methods: </strong>This study comprised a randomized, double-blind, placebo-controlled, single-dose escalation phase and an open-label, multiple-dose escalation phase. Ninety-four subjects received intramuscular injections of QHRD106/placebo only once and 30 subjects received QHRD106 four times. Six subjects received 0.15 PNA units UKN intravenously for 7 d. PK and PD analysis were conducted by using a electrochemiluminescent assay and a liquid chromatography/mass spectrometry methodology, respectively. Cerebral circulation was assessed by the magnetic resonance imaging system.</p><p><strong>Results: </strong>QHRD106 exhibited a slow absorption profile in the human body. Compared to UKN, QHRD106-induced changes in bradykinin concentration later, but with a noticeably prolonged duration. Compared to baseline, cerebral blood flow exhibited a significant improvement on d 7 after a single dose of 18,900 IU and an improvement from d 2 to d 14 after multiple doses of 8400 IU of QHRD106. QHRD106 appeared generally good safety and no severe adverse events occurred in all the groups.</p><p><strong>Conclusions: </strong>This study provided initial evidence of potential treatment for ischemic strokes that the QHRD106 injection functioned as a safe and effective long-acting kallikrein drug.</p><p><strong>Registration: </strong>This study was registered on ClinicalTrials.gov with the identifier NCT06380699 and NCT06388772.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1257-1265"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigational drugs in early phase trials for myelofibrosis. 骨髓纤维化早期试验中的研究药物。
IF 4.9 2区 医学
Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-11-27 DOI: 10.1080/13543784.2024.2434696
Sankalp Arora, Pankit Vachhani, Prithviraj Bose
{"title":"Investigational drugs in early phase trials for myelofibrosis.","authors":"Sankalp Arora, Pankit Vachhani, Prithviraj Bose","doi":"10.1080/13543784.2024.2434696","DOIUrl":"10.1080/13543784.2024.2434696","url":null,"abstract":"<p><strong>Introduction: </strong>Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, and organomegaly. Four JAK inhibitors are US-FDA approved for treatment of MF. While these drugs reduce symptom burden and spleen size to varying degrees, they do not affect the natural disease course or decrease the risk of leukemic transformation. Therefore, there is a strong need for newer therapies to further advance the field and improve the outcomes of MF. In this review, we cover novel therapies for MF currently in early stages of development.</p><p><strong>Areas covered: </strong>We present the latest data from early phase clinical trials in MF using drugs with diverse therapeutic mechanisms, including novel JAK-STAT pathway inhibitors, epigenetic therapies, antifibrotic agents, and immunotherapeutic strategies. Additionally, we cover drugs targeted toward anemia improvement in MF.</p><p><strong>Expert opinion: </strong>Numerous agents representing diverse drug classes are in clinical development for MF. While deeper and durable improvements in splenomegaly, symptoms, and anemia are the main clinical objectives, a number of putative biomarkers are being assessed as measures of potential 'disease modification.' Although JAK inhibitor monotherapy represents the current standard, it is hoped that JAK inhibitor-based rational combinations and driver mutation-specific therapies will soon usher in a new era.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1231-1244"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142738981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Hippo pathway as an antitumor target: time to focus on. 作为抗肿瘤靶点的 Hippo 通路:是时候关注了。
IF 4.9 2区 医学
Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-11-26 DOI: 10.1080/13543784.2024.2432395
Olga A Koroleva, Alexander V Kurkin, Alexander A Shtil
{"title":"The Hippo pathway as an antitumor target: time to focus on.","authors":"Olga A Koroleva, Alexander V Kurkin, Alexander A Shtil","doi":"10.1080/13543784.2024.2432395","DOIUrl":"10.1080/13543784.2024.2432395","url":null,"abstract":"<p><strong>Introduction: </strong>The Hippo signaling governs the expression of genes critically important for cell proliferation and survival. The components of this pathway are considered antitumor drug targets. However, the design of Hippo inhibitors is a challenge given the complexity of the network and redundancy of its elements.</p><p><strong>Areas covered: </strong>We review the current state-of-the-art in the structure of the Hippo pathway, the microenvironment-induced extracellular cues, the strategies to design pharmacological instruments for inactivation of the Hippo signaling using small molecular weight modulators, as well as the results of initial clinical trials.</p><p><strong>Expert opinion: </strong>One special characteristic of the Hippo signaling is the adverse role of phosphorylation: opposite to classical kinase cascades that activate the transcription factors, the Hippo kinases retain their partners in a transcriptionally inactive state. Therefore, approaches for pharmacological or genetic inhibition of Hippo protein kinases are counterproductive. The developing alternatives such as disruption of protein-protein interactions or PROTAC techniques are straightforward for preventing the Hippo signaling in cancer therapy.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1177-1185"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142727151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relaxin agonists under preclinical and early clinical investigation for the treatment of heart failure. 舒张素激动剂治疗心力衰竭的临床前和早期临床研究。
IF 4.9 2区 医学
Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-12-13 DOI: 10.1080/13543784.2024.2438663
Ashwin Ajay, Priyanga Biju, Hanan Ajay, Rajiv Tripathi, Gregory Y H Lip, Rajiv Sankaranarayanan
{"title":"Relaxin agonists under preclinical and early clinical investigation for the treatment of heart failure.","authors":"Ashwin Ajay, Priyanga Biju, Hanan Ajay, Rajiv Tripathi, Gregory Y H Lip, Rajiv Sankaranarayanan","doi":"10.1080/13543784.2024.2438663","DOIUrl":"10.1080/13543784.2024.2438663","url":null,"abstract":"<p><strong>Introduction: </strong>Acute failure is a critical condition, encompassed by the sudden or progressive onset of symptoms or signs of congestion. The treatment strategies available are mainly supportive and do not improve mortality or long-term outcomes. Therefore, there is a need for alternative novel treatment strategies. In this narrative review, we explore the role of relaxin agonist as a potential therapeutic strategy in acute heart failure.</p><p><strong>Areas covered: </strong>We aim to provide an overview of the evidence of preclinical and clinical studies on relaxin as a treatment strategy for acute heart failure. Papers collected in this review are from original research and systematic reviews which have been filtered following Medline and Cochrane Library searches.</p><p><strong>Expert opinion: </strong>Relaxin has shown great potential in both preclinical and clinical studies due to its antifibrotic, anti-inflammatory, and vasodilatory effect on the heart. However, there has been mixed evidence from clinical trials involving relaxin which could be due to patient groups, investigation sites, trial design, and chance. Further studies should focus on developing biomarkers to identify specific population groups who are most likely to benefit from relaxin.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1209-1218"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan as a novel treatment strategy to alleviate IgA nephropathy. 用司帕生坦双重阻断内皮素 A 和血管紧张素 II 1 型受体,作为缓解 IgA 肾病的新型治疗策略。
IF 4.9 2区 医学
Expert opinion on investigational drugs Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI: 10.1080/13543784.2024.2414902
Hajime Nagasawa, Hitoshi Suzuki, Seiji Ueda, Yusuke Suzuki
{"title":"Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan as a novel treatment strategy to alleviate IgA nephropathy.","authors":"Hajime Nagasawa, Hitoshi Suzuki, Seiji Ueda, Yusuke Suzuki","doi":"10.1080/13543784.2024.2414902","DOIUrl":"10.1080/13543784.2024.2414902","url":null,"abstract":"<p><strong>Introduction: </strong>Although immunoglobulin A nephropathy (IgAN) had been discovered more than 50 years ago, 30-40% of IgAN patients still have primary glomerular disease that progresses to end-stage renal disease. However, various treatment strategies for IgAN have rapidly expanded in recent years to include endothelin (ET) receptor antagonists.</p><p><strong>Areas covered: </strong>In this review, we discuss the role of the ET-1/ET<sub>A</sub> receptor axis in the development of IgAN, especially focusing on the potential of sparsentan, a dual ET and angiotensin receptor antagonist as a novel therapy for IgAN.</p><p><strong>Expert opinion: </strong>Evaluation of the MEST-C score at the time of renal biopsy in IgAN is important in determining treatment strategies. If lesions are mainly in the acute phase, such as crescents, steroid therapy should be continued. However, if lesions are mainly in the chronic phase, such as glomerulosclerosis, sparsentan rather than steroid or angiotensin II receptor blocker alone may improve renal outcomes. Although further clinical studies are needed to back up these assumptions, appropriate combination of new drugs containing sparsentan and conventional drugs for IgAN treatment at the appropriate disease stage is expected to further inhibit the progression of renal damage.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1143-1152"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Theranostic strategies in sarcoma: preliminary clinical evidence. 肉瘤的血清疗法策略:初步临床证据。
IF 4.9 2区 医学
Expert opinion on investigational drugs Pub Date : 2024-11-01 Epub Date: 2024-10-09 DOI: 10.1080/13543784.2024.2414119
Luca Filippi, Cristina Ferrari, Giuseppe Rubini
{"title":"Theranostic strategies in sarcoma: preliminary clinical evidence.","authors":"Luca Filippi, Cristina Ferrari, Giuseppe Rubini","doi":"10.1080/13543784.2024.2414119","DOIUrl":"10.1080/13543784.2024.2414119","url":null,"abstract":"<p><strong>Introduction: </strong>Sarcomas encompass a highly diverse range of malignancies, characterized by varied morphological and molecular profiles. Treatment options in case of therapy-refractory or advanced disease are limited. In this context, theranostics emerges as an innovative platform seamlessly integrating diagnosis and therapy, offering promising prospects.</p><p><strong>Areas covered: </strong>This special report delves into the initial clinical applications of theranostic-based approaches in sarcomas. Specifically, it examines various strategies targeting biomarkers associated with sarcomas, including fibroblast activation protein (FAP), prostate-specific membrane antigen (PSMA), C-X-C chemokine receptor type 4 (CXCR4) and somatostatin receptor 2 (SSTR2).</p><p><strong>Expert opinion: </strong>The heterogeneous uptake of the CXCR4-targeted radioligand in lesions, along with its poor correlation with immunohistochemistry data, diminishes the attractiveness of this theranostic approach in the sarcoma oncological setting. SSTR2-targeted approaches in sarcoma, although potentially effective, are limited to a single case. Early experiences with FAP inhibitors in sarcoma patients have shown particularly promising outcomes, indicating effective disease control with minimal toxicity. While PSMA presents an enticing target for theranostic approaches in sarcomas, its utilization remains anecdotal and requires further investigation. Prospective and well-designed clinical trials are imperative to delineate the potential impact of FAPI- and PSMA-based approaches on sarcoma therapeutic landscapes, offering innovative and personalized treatment options.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1119-1127"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiviral agents and therapeutics against respiratory viruses. 针对呼吸道病毒的抗病毒剂和疗法。
IF 4.9 2区 医学
Expert opinion on investigational drugs Pub Date : 2024-11-01 Epub Date: 2024-09-08 DOI: 10.1080/13543784.2024.2401911
Ralph A Tripp, David E Martin
{"title":"Antiviral agents and therapeutics against respiratory viruses.","authors":"Ralph A Tripp, David E Martin","doi":"10.1080/13543784.2024.2401911","DOIUrl":"10.1080/13543784.2024.2401911","url":null,"abstract":"<p><strong>Introduction: </strong>Respiratory viruses are responsible for significant worldwide morbidity and mortality. While vaccines are highly effective at reducing the morbidity and mortality associated with viral infections, this protection is incomplete. It requires a high degree of compliance, which is hindered by vaccine hesitancy. To address these gaps, antiviral agents and therapeutics are crucial in combating diseases caused by respiratory viruses. Antiviral agents are broadly classified into two groups: 1) direct-acting antivirals (DAA) and 2) host-directed antivirals (HDA).</p><p><strong>Areas covered: </strong>This review comprehensively examines Phase II FDA-approved antiviral drugs for influenza virus, SARS-CoV-2, and RSV as published in clinicaltrials.gov. It focuses on DAAs and various monoclonal antibodies (mAbs) that have been approved for the prevention and treatment of viral respiratory tract infections.</p><p><strong>Expert opinion: </strong>Antiviral drugs being developed assess different mechanisms of action to combat viruses and other delivery routes (i.e. oral, inhalation, or parenteral). The associated clinical trials address the impact on disease while determining the appropriate dosage levels for further investigation in Phase III. A robust pipeline of agents is necessary to meet the global need for effective antiviral therapeutics.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1129-1133"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信